Remove Cardiogenic Shock Remove Myocardial Infarction Remove STEMI
article thumbnail

Cardiogenic Shock

American College of Cardiology

The goal of the DanGer Shock trial was to compare the safety and efficacy of Impella CP on top of standard care compared with standard care alone among patients with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock.

article thumbnail

Heart pump increases survival in STEMI-related cardiogenic shock

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 23 April 2024; doi:10.1038/s41569-024-01035-9 Data from the DanGer Shock trial demonstrate that implantation of a microaxial flow pump in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock increases the survival rate compared with standard care alone.

article thumbnail

How cardiogenic shock in NSTEMI is different from STEMI?

Dr. S. Venkatesan MD

Cardiogenic shock (CS)is the most feared event following STEMI. We tend to perceive CS as an exclusive complication of STEMI. The incidence is half of that of STEMI, i.e., 2.5-5%. might show little elevation with considerable overlap of left main STEMI vs NSTEMI ) 2.Onset How is CS in NSTEMI different ?

article thumbnail

Facility-based approach for the management of acute ST segment elevation myocardial infarction with cardiogenic shock in a rural medical centre: the Durango model

Open Heart

Introduction Cardiogenic shock (CS) complicates 5%–15% of cases of acute myocardial infarction (AMI) with inpatient mortality greater than 40%. This prospective registry includes all patients >18 years of age presenting with STEMI with or without CS beginning on 1 February 2023.

article thumbnail

Adherence to optimal medical therapy and control of cardiovascular risk factors in patients after ST elevation myocardial infarction in Mexico

Frontiers in Cardiovascular Medicine

IntroductionIn developing countries, there is a notable scarcity of real-world data on adherence to optimal medical therapy (OMT) and its correlation with major cardiovascular adverse events (MACEs) after ST-elevation myocardial infarction (STEMI). Patients were followed up for 4.5 years (±10.9), predominantly male (89.9%).

article thumbnail

Stress hyperglycemia and poor outcomes in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis

Frontiers in Cardiovascular Medicine

Background Hyperglycemia, characterized by elevated blood glucose levels, is frequently observed in patients with acute coronary syndrome, including ST-elevation myocardial infarction (STEMI). There are conflicting sources regarding the relationship between hyperglycemia and outcomes in STEMI patients.

article thumbnail

Angiography-Derived Index of Microcirculatory Resistance to Define the Risk of Early Discharge in STEMI

Circulation: Cardiovascular Interventions

BACKGROUND:Patients with ST-segment–elevation myocardial infarction but no coronary microvascular injury are at low risk of early cardiovascular complications (ECC). CONCLUSIONS:NH-IMRangiois a valuable risk-stratification tool in patients with ST-segment–elevation myocardial infarction.